AI for Pharma and Life Sciences Companies: Use Cases and the 2026 Tool Landscape

A single new drug submission can run to hundreds of thousands of pages, every one of which must be traceable, defensible, and signed by a qualified person. A single deviation on a production line can take a quality team 30 to 45 days to investigate and close by hand¹⁴. A single adverse event report has to be intake, coded, assessed, and filed against a regulatory clock. Pharma and life sciences companies run on documents, data, and deadlines - and they run short of the people to handle all three.

This is exactly where AI pays back. McKinsey estimates generative AI could unlock 60 to 110 billion dollars a year in value across the pharma and medical-products industries, and that 75 to 85 percent of pharma and medtech workflows can be enhanced or automated by AI agents¹³. Yet only about 5 percent of companies have turned any of it into a consistent financial advantage². The tools exist. The gap is in how they are strung together - and in what happens to your hard-won expertise when a senior person walks out the door.

This guide is the honest version for the operations, quality, regulatory, or IT leader at a pharma, biotech, CDMO, or life sciences company. The real processes where AI works, the real 2026 tool landscape named by name, the regulated-industry constraints that actually matter, and the connective layer most point tools leave out.

The Regulated-Industry Paradox

Pharma and life sciences companies are, on paper, the perfect candidates for AI: process-driven, data-rich, and full of repetitive, high-volume document work. And yet they adopt more slowly than almost any other sector, for reasons that are entirely rational. The same rigour that makes the work valuable makes it hard to automate casually.

• The value is enormous and mostly on the table - McKinsey estimates gen AI could unlock 60 to 110 billion dollars a year across pharma and medical products, with 18 to 30 billion in commercial alone and 4 to 7 billion in biopharma operations.¹
• Almost nobody has captured it yet - Only around 5 percent of life sciences companies have turned gen AI into a consistent financial differentiator; the rest are stuck in experimentation.²
• Data lives in validated silos - Information sits in GxP-validated systems that cannot be casually modified without affecting regulatory standing, and decades of acquisitions have left incompatible architectures.¹⁸
• The talent gap is structural - The pharma and life sciences sector is short of a large share of the talent it needs, and an ageing workforce means senior expertise is retiring faster than it is replaced.²⁰
• Manufacturing feels it most - Roughly 80 percent of pharmaceutical manufacturing facilities report struggling with skills mismatches, and experienced staff are the hardest roles to fill.²⁰²¹
• Projects die without a data foundation - Gartner expects organisations to abandon a large share of AI projects that are not supported by AI-ready data, a problem that bites hardest in fragmented regulated estates.¹⁸

This is the paradox: the companies with the most to gain from AI are the ones with the most reasons to be careful. The answer is not to lower the bar. It is to bring AI up to the bar - validated, audited, and grounded in the company’s own knowledge.

Why Institutional Knowledge Is the Asset

A pharma company sells products, but it runs on knowledge: how to write a submission the agency will accept, how to investigate a deviation without over-scoping it, how to assess a safety signal, how to transfer a process from development to a commercial line. That knowledge is the actual engine, and it has a dangerous property - most of it lives in individual heads and in systems that do not talk to each other.

• The workforce is ageing out - A large wave of experienced staff is approaching retirement, and there are not enough new entrants to replace the expertise they carry.²⁰
• The gap is already structural - The sector is short of a significant share of the talent it needs, with senior regulatory, quality, and manufacturing roles among the hardest to fill.²⁰²¹
• Knowledge is trapped in validated silos - The QMS, the LIMS, the safety database, the eTMF, the ERP, and a thousand SharePoint folders each hold a slice, and none holds the whole.¹⁸
• Tribal knowledge never gets written down - How a veteran investigator spots the real root cause, or how a writer handles a specific agency’s expectations, rarely makes it into any document.
• Every exit is a small crisis - When a senior person leaves, the next team relearns what the company already knew, adding delay and compliance risk to the next submission or investigation.
• Reuse is the profit lever - Companies that capture and reuse methodology, past submissions, and investigation logic move faster and more consistently than those starting from a blank page each time.

What actually needs capturing

Reusable expertise in a life sciences company is not a folder of old files. It is the working knowledge that makes the company effective and compliant, and most of it is never formally recorded.

• How you write for each agency - The structure, tone, and evidence standard that gets a submission through the FDA, EMA, or a national authority without a cycle of questions.
• How you investigate - The way an experienced QA lead scopes a deviation, avoids over-investigation, and lands on a root cause that holds up in an audit.
• How you assess safety - The judgment that turns a raw adverse event into a coded, assessed, and correctly escalated case.
• How you transfer a process - The tacit knowledge that moves a product from development into a validated commercial line without losing a month.
• Who knows what - The map of which person led which validation, filing, or investigation, so the next team finds the expert, not just the file.
• What went wrong before - The lessons from findings, recalls, and rejected submissions that shape good judgment but rarely reach a document.

This is the lens for everything that follows. Every AI use case below is really a question of turning individual expertise into company expertise the whole team - and its AI employees - can reuse, inside a system a regulator would accept.

7 AI Use Cases That Deliver in Life Sciences

These are the processes where pharma and life sciences companies see the clearest return today. Each is a routine, high-volume task that eats expert time, sits on top of knowledge the company already owns, and already has a human review step where AI can slot in safely.

1. Regulatory and medical writing

• The problem - Clinical study reports, submission modules, and medical documents run to enormous length and pull scarce medical writers into repetitive, template-driven drafting.
• What AI does - Extracts data from tables, listings, and datasets, and drafts narrative sections against approved templates; Yseop’s Clinical Atlas generates first-draft narratives from TLFs and ADaM datasets for a writer to refine.⁹¹⁰
• Why it pays - Organisations report more than 50 percent reductions in document creation time and submission timelines cut by weeks to months, with better traceability and consistency.⁹
• Real example - Novartis invested in Yseop to automate elements of clinical trial report writing, keeping a medical writer in the loop for review and sign-off.¹⁰
• Watch for - Confident but wrong text and unvalidated tools; any AI touching a submission record must be validated, and a qualified writer owns the final document.¹⁵

2. Quality, QMS, deviations and CAPA

• The problem - A busy site can generate hundreds of deviations a month, each needing classification, investigation, and a linked CAPA, and each taking weeks to close by hand.¹³
• What AI does - Classifies events by severity, suggests likely root causes from similar past cases, and drafts the investigation and CAPA; TrackWise offers AI-assisted auto-categorisation and MasterControl adds predictive quality analytics.¹²¹³
• Why it pays - Industry reporting describes deviation cycles falling from a typical 30 to 45 days toward 7 to 10 days with AI-assisted workflows, with a reviewer still owning closure.¹⁴
• Real example - A quality team opens a new deviation and receives a suggested classification, three similar historical cases, and a draft investigation grounded in the site’s own history.
• Watch for - Treating the AI suggestion as the decision; classification and CAPA closure remain a qualified reviewer’s call, logged in the audit trail.

3. Pharmacovigilance and safety case intake

• The problem - Adverse event volumes keep rising, arrive in many formats and languages, and must be processed against strict regulatory clocks.
• What AI does - Reads reports, extracts the structured case fields, translates, and drafts the narrative; ArisGlobal reports up to 65 percent faster intake and around 90 percent intake-data accuracy on LifeSphere.⁷⁸
• Why it pays - Case intake is the highest-volume, most repetitive step in safety, and NavaX translation cut per-case translation from about five hours to under a minute.⁸
• Real example - A safety officer opens a pre-populated case with extracted fields and a drafted narrative, and spends their time on medical assessment rather than transcription.
• Watch for - Medical judgment and causality assessment stay human; AI accelerates intake, it does not decide the seriousness of a case.²²

4. R&D and lab knowledge

• The problem - Scientific knowledge is scattered across notebooks, instruments, and free-text entries, and nobody can query it as data.
• What AI does - Grounds answers in structured R&D data so scientists can find experiments, analyse results, and draft reports; Benchling AI connects agents directly to structured notebook and registry data.¹¹
• Why it pays - The AI use cases with the highest adoption succeed because the underlying data is clean, structured, and verifiable, which is the hard part in the lab.¹¹
• Real example - A scientist asks the platform to find prior experiments on a target, pull the results, and draft a summary, grounded in the team’s own structured data rather than a blank prompt.
• Watch for - Free-text notebooks that AI cannot reliably parse; the value comes from structured, typed scientific data, not scanned PDFs.

5. Commercial and medical affairs

• The problem - Field teams, MLR review, and medical information handle high volumes of content and enquiries under strict promotional and compliance rules.
• What AI does - Prepares field reps for calls, flags compliance issues in content before medical, legal, and regulatory review, and drafts medical-information responses; Veeva ships Pre-call, Quick Check, and Content agents in Vault CRM and PromoMats.⁵
• Why it pays - Commercial is where McKinsey sees the largest single value pool, 18 to 30 billion dollars a year, because the content and interaction volume is so high.¹
• Real example - A rep opens a pre-call brief assembled from recent activity and content, and a reviewer receives a compliance pre-check before MLR sign-off.
• Watch for - Promotional and off-label rules are strict; the AI narrows what a reviewer checks, it does not approve claims.

6. Supply, serialization and track-and-trace

• The problem - Serialized data now flows through the supply chain under DSCSA in the US and FMD in the EU, and recalls, exceptions, and reconciliation are manual and time-critical.¹⁷
• What AI does - Reads the rich serialized and logistics data to flag exceptions, speed recall management, and forecast supply risk across trading partners.¹⁷
• Why it pays - More than 78 countries now mandate serialization, so the data exists; the value is turning that data into faster decisions rather than reports nobody reads.¹⁷
• Real example - A serialized recall that once took days to scope is narrowed to the affected lots and trading partners in hours, with the actions drafted for a human to approve.
• Watch for - Supply data quality and partner interoperability; AI on messy serialized data still needs a human owning the recall decision.

7. Knowledge search across GxP systems

• The problem - The answer to a question usually exists somewhere in the QMS, the eTMF, email, or SharePoint, but nobody can find it or the person who wrote it.
• What AI does - Indexes past work across connected systems so anyone can ask a question and get the right SOP, the past investigation, and the expert behind it, respecting access controls.
• Why it pays - It directly attacks the knowledge that would otherwise leave with retiring staff and sits fragmented across validated silos.¹⁸
• Real example - A new hire asks how the company handled a similar out-of-specification result and gets the past investigation, the SOP, and the person who led it.
• Watch for - Access leaks across trial and product walls; search must honour the same permissions as the underlying validated systems.

None of these seven is exotic. Every one is a task your company already does by hand every week, on top of knowledge you already own, with a human review step already built in. That is exactly why they pay back and why they are the right place to start rather than a moonshot drug-discovery project that never reaches operations.

AI by Company Type: Where to Start

Life sciences is not one thing. A large pharma, a clinical-stage biotech, a CDMO, a generics maker, and a medtech or diagnostics company live on different work, so the first AI move differs. What stays constant is the pattern: automate the routine, capture the expertise, keep judgment and sign-off human, and validate the system.

Large pharma

• The bottleneck - Enormous submission, safety, and quality volumes across many products and geographies, spread over incompatible legacy systems.
• Best first move - Regulatory writing and pharmacovigilance intake, where volume is highest and a review step already exists.
• The knowledge risk - Expertise fragmented across acquired sites and retiring specialists; a connected memory is the way to keep it.

Biotech and clinical-stage companies

• The bottleneck - Small teams carrying heavy R&D and regulatory load with little administrative slack.
• Best first move - Structured R&D knowledge and knowledge search, so a lean team reuses everything it produces.
• The knowledge risk - Key-person dependence is extreme; when one scientist leaves, a program can stall, so capture as work happens.

CDMOs and contract manufacturers

• The bottleneck - High deviation and change-control volume across many clients, each with its own quality expectations.
• Best first move - Deviation and CAPA drafting plus knowledge search across the QMS, where cycle time is directly billable.
• The knowledge risk - Client-specific know-how and process transfers live in a few heads; a shared brain keeps them across staff turnover.

Generics and established products

• The bottleneck - Thin margins and high filing volumes reward efficiency over novelty.
• Best first move - Document processing, variations, and quality automation, where reused templates cut the most time.
• The knowledge risk - Repetitive work masks how much sits in undocumented routine; capture the routine before the people who know it leave.

Medtech and diagnostics

• The bottleneck - Technical files, complaint handling, and post-market surveillance under device regulation and, where AI is a device component, its own conformity route.
• Best first move - Complaint intake, technical documentation, and knowledge search across product lines.
• The knowledge risk - Product and vendor knowledge scatters across teams; a shared brain makes it reusable across the portfolio.

The 2026 AI Tool Landscape for Life Sciences

The market is crowded and moving fast. Below is an honest map of the real, current tools life sciences companies actually use, grouped by the job they do. No single tool covers a company end to end, and most run several. Superkind appears in exactly one place - the knowledge layer underneath - and we will be clear about where the specialist platforms are the better fit.

Regulatory and medical writing

These generate first drafts of regulated documents from data and templates, and they are strongest with a qualified writer reviewing every line.

• Yseop - Regulatory-grade automation for CSRs and medical writing, extracting data from TLFs and datasets into narrative.⁹
• Certara and ArisGlobal - Regulatory and medical writing automation across the submission lifecycle.¹⁰
• Veeva Vault RIM and Medical - Regulatory information management and medical content, with task-specific agents rolling out through 2026.⁵

Quality, QMS and CAPA

These run deviations, CAPA, change control, and complaints, increasingly with AI classification and predictive analytics on top.

• Veeva Vault QMS - Cloud quality management with agents planned across quality workflows in 2026.⁵
• MasterControl - Long-established QMS with the Insights AI analytics module for predictive quality.¹²
• Honeywell TrackWise - Formerly Sparta Systems, a market leader for high-volume deviation and CAPA with AI-assisted auto-categorisation.¹³

Pharmacovigilance and safety

These process safety cases end to end, with intake automation the most mature AI application in the category.

• ArisGlobal LifeSphere - Market-leading PV platform with GenAI-powered intake and the NavaX agents.⁷⁸
• Oracle Argus and Veeva Vault Safety - Established safety databases adding AI-assisted processing.²²

R&D and the lab

These structure scientific data so AI can act on it, which is the precondition for useful lab AI.

• Benchling - Cloud R&D platform with Benchling AI grounded in structured notebook and registry data.¹¹
• Dotmatics and LIMS platforms - Research informatics and lab data management across the R&D estate.

Commercial, medical affairs and supply

These cover field, content, and the serialized supply chain, where interaction and data volumes are highest.

• Veeva Vault CRM and PromoMats - Field and content management with Pre-call, Quick Check, and Content agents.⁵
• TraceLink and Systech - Serialization and supply-chain track-and-trace under DSCSA and FMD.¹⁷

Horizontal and knowledge

These sit across everything, help people find and draft, and are closest to the knowledge layer without retaining living, validated know-how.

• Microsoft 365 Copilot and Glean - Drafting and enterprise search across connected apps and documents.
• ChatGPT Enterprise and Veeva Falcon - General reasoning, and Falcon’s agentic platform for TMF intake, safety case intake, and health-authority interaction.⁶

How to evaluate a tool for a regulated company

Before adding another platform, run it through five questions that matter more than the feature list.

1. Can it be validated? - Does the vendor support computer system validation under GAMP 5, with documented data provenance and qualification testing? For GxP records this is the first filter, not the last.¹⁶
2. Where does the data go? - Does trial, patient, and proprietary data stay in your environment, and is it excluded from public model training?
3. Is the audit trail sound? - Are AI actions computer-generated, time-stamped, and tamper-evident, as 21 CFR Part 11 and Annex 11 require?¹⁵
4. Can it see your real work? - A tool that only works from a blank prompt gives generic output; one that connects to your validated systems reuses what the company knows.
5. Does the knowledge stay? - When the subscription ends or the person leaves, does anything the tool learned about your company remain, or does it walk out with them?

The Missing Layer: A Company Brain

A Company Brain is a private, living memory of your organisation - the people-knowledge, processes, and past work that normally lives in individual heads and scattered validated systems. It is the layer that turns a pile of point tools into a system that actually knows your company, and it is where AI employees get the context to do useful work inside a controlled environment.

• It retains expertise - Captures how your best writers, investigators, and process experts work, so their know-how stays when they retire or move on.²⁰
• It grounds every AI tool - A CAPA draft, a submission section, or a medical response is only as good as the company knowledge behind it; the brain provides that context.
• It connects validated systems - Email, Teams, SharePoint, Veeva or another CRM, the ERP, the LIMS, and the QMS, so knowledge is drawn from where work already happens.
• It learns from feedback - Every corrected draft and every reused investigation teaches it what good looks like at your company.
• It powers AI employees - With the brain underneath, an AI employee can read a deviation, pull the related batch record, and draft the investigation in one flow.
• It stays under your control - Private to your company, with access controls and audit logs, so trial, patient, and proprietary data never reaches a public model.
• It works across functions - The same layer that helps quality also helps regulatory, safety, and the lab, because they all draw on the same company memory.
• It shortens onboarding - A new hire asks the brain how the company does things instead of interrupting a senior colleague, reaching productive faster.
• It compounds - Unlike a tool that resets with each task, the brain gets more valuable the longer the company uses it, because it holds more of what the company knows.

This is the distinction between an AI copilot and an AI employee. A copilot helps a person inside one app. An AI employee, grounded in a Company Brain and supervised by your people, takes over a routine job across your systems with human checkpoints where they matter.

The AI employees a life sciences company actually deploys

In practice, the AI employees map to the routine roles that fill a company’s week - each grounded in the Company Brain, validated, and supervised by a qualified person.

• The regulatory writer - Turns data and templates into a first-draft submission section in the company’s house style, ready for a writer to refine.
• The quality investigator - Classifies a deviation, surfaces similar past cases, and drafts the investigation and CAPA for a QA reviewer.
• The safety intake officer - Reads adverse event reports, extracts and translates the case fields, and drafts the narrative for medical assessment.
• The knowledge keeper - Captures decisions, investigations, and context as work happens, so nothing leaves with the person who did it.
• The coordinator - Prepares meeting summaries, actions, and status updates across teams, keeping the admin off expert plates.

GxP, Validation, and the EU AI Act

In a regulated industry, the question is never just “does the AI work” but “can you prove it, and who signs”. The good news is that the frameworks already exist and are being extended for AI. The bad news is that shortcuts here are how companies get a finding. Here is what actually applies.

Validation and the audit trail

• AI that touches a GxP record is validated software - A batch record, deviation, submission, or safety case brings the AI into computer system validation under GAMP 5.¹⁶
• GAMP 5 now covers AI - The 2022 second edition and the ISPE GAMP AI Guide give a lifecycle where the validation plan documents data provenance and model design, and qualification challenges the algorithm against known cases.¹⁶
• Audit trails are non-negotiable - 21 CFR Part 11 and EU Annex 11 require secure, computer-generated, time-stamped audit trails that operators cannot modify or disable.¹⁵
• Electronic signatures bind to records - A qualified person’s signature is bound to the record, so accountability stays with a human, not the model.¹⁵
• Monitor for drift - AI models can change behaviour as data shifts, so ongoing monitoring is part of keeping the system in a validated state.¹⁶

The regulatory picture in 2026

• FDA finalised CSA guidance - The Computer Software Assurance guidance, final in September 2025, encourages risk-based, less document-heavy assurance for lower-risk systems.¹⁶
• The EU is drafting AI-specific rules - A proposed Annex 11 revision and a new Annex 22 on artificial intelligence remain draft guidance, signalling where GMP expectations are heading.¹⁶
• FDA and EMA aligned early - The regulators jointly released good-practice principles for AI in drug development in early 2026, a useful north star even before binding rules.¹⁶
• The EU AI Act becomes fully applicable - From August 2026, with most pharma operational AI in the minimal or limited-risk tiers and AI literacy training required for users.²³
• Pharmacovigilance draws extra scrutiny - AI used in safety carries specific governance expectations, since it touches patient safety directly.²²

How to Build Your AI Stack

The companies that get value do not buy the most tools - they validate one workflow well and expand from there. Here is a practical sequence that avoids subscription sprawl and pilot purgatory, without cutting a compliance corner.

1. Pick one high-return, review-backed workflow - Choose a routine, high-volume task where the return is obvious and a human already reviews the output: safety intake, deviation drafting, or knowledge search. One workflow, not five.
2. Baseline the current cost - Measure the hours and cycle time the workflow eats today and the quality problems it creates. You cannot prove value against a number you never took.
3. Set the compliance frame first - Agree the validation approach, the data-sovereignty rules, and the human sign-off points before any tool touches a GxP record.
4. Start the knowledge layer - Point the Company Brain at the systems this workflow already uses - the QMS, the safety database, SharePoint - so drafts reuse real company knowledge from day one.
5. Add the specialist tool where it fits - Use the best validated platform for the task on top of that context, rather than a generic model working from a blank prompt.
6. Keep a qualified human in the loop - Define the checkpoints where a person reviews and signs before anything is filed. Non-negotiable for accuracy and accountability.
7. Measure time saved, not tools bought - Track hours recovered and cycle time against the baseline, and log everything for the eventual audit.
8. Capture as you go - Every reviewed draft and correction feeds the brain, so the next investigation or submission starts further ahead.
9. Expand to the next workflow - Once the first runs in a validated state, reuse the same knowledge layer for the next. The context compounds.

For most companies the answer is both: specialist platforms for validated tasks, sitting on a connected knowledge layer so their output is grounded in the company rather than the open internet.

Common mistakes to avoid

Most AI disappointment in life sciences traces back to the same handful of avoidable errors.

• Buying tools before mapping the workflow - A platform does not fix a process nobody has looked at; map the work first, then choose the tool.
• Skipping validation and hoping - Unvalidated AI on a GxP record is a finding waiting to happen; set the compliance frame before you start.
• Pasting regulated data into public chatbots - The fastest route to a data-sovereignty breach; decide where data may go before anyone touches real records.
• Skipping the baseline - Without a before number, you can never prove the after, and the pilot dies in a debate about whether it worked.
• Treating AI output as final - Confident, wrong drafts reach a submission when human review is optional; make the sign-off mandatory.
• Ignoring adoption - The best platform nobody opens returns nothing; put AI inside the systems people already use.
• Not capturing what the AI learns - If corrections and reused work do not feed a shared brain, the company relearns the same lessons on every project.
• Starting with drug discovery - The moonshot is tempting, but operations workflows with a review step pay back sooner and de-risk the harder projects.

A 90-day path to your first win

You do not need a multi-year transformation programme. A focused quarter takes one validated workflow from idea to a measured result.

1. Weeks 1 to 3: choose, baseline, and frame - Pick the single workflow, map how it runs today, record the hours and cycle time, and agree the validation approach and data rules before any tool touches a record.
2. Weeks 4 to 8: connect and build - Point the knowledge layer at the systems the workflow already uses, add the right platform on top, and define the human sign-off points. Your team works with it on real cases and gives feedback.
3. Weeks 9 to 12: measure and expand - Compare hours and cycle time against the baseline, document the validation evidence, capture the knowledge produced, and decide the next workflow. The first win funds and de-risks the second.

How Superkind Fits

Superkind builds two things for life sciences companies: a Company Brain that retains your organisation’s expertise, and AI employees that take over routine work on top of it. The approach is process-first - we start from how your teams actually write, investigate, and process cases, not from a generic product you have to adapt to.

• Company Brain - A private, living memory of your people-knowledge, processes, and past work that stays even when a senior specialist retires.
• AI employees - Agents that draft submissions, investigations, and safety narratives, and capture knowledge, grounded in the brain and supervised by your people.
• Connected to your systems - Email, Teams, SharePoint, Veeva or another CRM, the ERP, the LIMS, and the QMS, so work happens where it already lives.
• Process-first discovery - We map the real workflow with the people who do it before building anything. No templates, no slideware.
• Built for regulated environments - Runs in your controlled environment with access controls and audit trails, so trial, patient, and proprietary data never reaches a public model.
• Learns by daily feedback - Your team corrects and reuses, and the system sharpens to how your company actually works.
• More output without headcount - The goal is more done, and less expertise lost, from the people you already have.
• Outcome-based pricing - Priced per use case against measurable results, not per seat.
• Model-agnostic - The brain is not tied to one AI provider, so you can use the best model for each task without rebuilding your knowledge layer.
• Starts small - One validated workflow proves the value before you expand, so the risk is contained and the first result funds the next.

If you only need a validated safety database or a QMS of record, buy the specialist platform. Superkind is for companies that want to stop losing expertise and give their AI something real, and controlled, to work from.

What stays human

The point of this is not to remove people from life sciences. It is to remove the routine so people do the work only they can do. In a regulated industry the line is not just good practice - it is the law.

• The medical and scientific judgment - Assessing a safety case, a root cause, or a claim is the expert work AI drafts toward but never owns.
• The regulatory strategy - How to position a submission and answer an agency is human judgment built over years.
• Accountability and sign-off - A qualified person carries responsibility for every filed record; an AI cannot be liable to a health authority.
• The final review - Every document that leaves the company passes a human who owns its accuracy and compliance.
• The judgment calls under uncertainty - The situations no template covers run on experience the machine supports but does not replace.

Decision Framework: What Should Your Company Do Now?

Not every company needs the same thing. Here is a framework to match your situation to a sensible first move.

Frequently Asked Questions

Related Articles

• AI for Professional Services Firms - the same honest use-case and tool-landscape treatment for consultancies and advisory firms.
• The Best AI Compliance and Audit Tools - what AI does for compliance evidence and audit readiness.
• AI for Food and Beverage Companies - AI in another quality-critical, regulated manufacturing industry.
• The Best AI Supply Chain Tools - how AI reads supply data to flag exceptions and risk.
• The Model-Agnostic Company Brain - why your knowledge layer should not be tied to one AI provider.
• The Bus Factor - what it really costs when critical knowledge lives in one person’s head.

Henri Jung

Co-founder of Superkind, where he helps SMEs and enterprises deploy custom AI agents that actually fit how their teams work. Henri is passionate about closing the gap between what AI can do and the value it creates in real companies. He believes the Mittelstand has everything it needs to lead in AI - it just needs the right approach.